Convenient In-Pharmacy Testing Now
Available in 900 Stores Nationwide
SAN DIEGO and BOISE, Idaho, March 22,
2022 /PRNewswire/ -- Cue Health Inc. (Nasdaq: HLTH), a
healthcare technology company, and Albertsons Companies (NYSE: ACI)
today announced a first-of-its-kind partnership that offers
customers access to Cue's highly accurate, convenient, and fast
molecular COVID-19 tests at participating Albertsons Cos.
pharmacies across the country. Pharmacy personnel will provide this
new service, which will allow customers to get Cue's lab-quality
COVID-19 test results delivered to their email in 20 minutes.
Albertsons Cos. and Cue piloted this in-pharmacy COVID-19
testing program last fall in 40 pharmacies in the state of
Washington and at Lumen Field for
fans attending Seattle Seahawks home games. The companies have
since rolled out the offering into approximately 900 pharmacies and
expect the test to be available at most Albertsons Cos. pharmacies
over the coming weeks.
"This collaboration encapsulates what we believe is a critical
component to the future of diagnostics: immediate access to
convenient, fast, and highly accurate testing solutions on the go,"
said Ayub Khattak, Co-founder and
CEO of Cue Health. "Whether individuals require testing for travel,
work, or peace of mind, in-pharmacy testing at Albertsons stores
removes barriers and provides real-time data that enables customers
to make more informed decisions. We are excited to work with
Albertsons to offer more customers access to our innovative testing
technology as we work to usher in the digital transformation of
personalized healthcare."
"To offer customers convenient, quick and accurate solutions we
have partnered with Cue Health to feature these tests in our
community pharmacies. Adding this diagnostic test expands options
for our customers to access proactive health and wellness solutions
at our stores," said Omer Gajial, Albertsons Cos. EVP of Pharmacy
and Health.
Customers can schedule a Cue test at an Albertsons Cos. pharmacy
at www.scheduletest.com. Walk-ins and appointments are also
available through the Albertsons Cos. local banner app for people
ages 2+. Testing under the age of 18 requires parental consent and
must have a guardian present.
As a nucleic acid amplification test (NAAT), Cue's molecular
COVID-19 test meets current testing entry requirements in many
countries around the world, including international air travel into
the U.S. and Canada, and the
results are often accepted by employers, schools, and sports and
entertainment venues.
Cue's molecular COVID-19 test is known for its accuracy and has
the distinct advantage of serving the needs of people with vision
loss, who cannot as easily use the rapid antigen tests offered by
the federal government's free testing program.
Cue's COVID-19 test is currently being used in point-of-care
settings across the country and is authorized for at-home use as
well, with data showing that it is the most accurate* self-test for
COVID-19. Cue provides tests to world-class organizations like
Johns Hopkins Medicine, Mayo Clinic, Google, the National
Basketball Association (NBA), and Major League Baseball (MLB),
among many others. Looking ahead, Cue is working on new diagnostic
tests - including for other respiratory illnesses, sexual diseases,
cardiometabolic health, and more - all of which will be compatible
with the reusable Cue Health Monitoring System (Cue Reader).
*Based on clinical study results submitted to FDA for other
EUA molecular home tests.
About Cue Health
Cue Health (Nasdaq: HLTH) is a healthcare technology company
that makes it easy for individuals to access health information and
places diagnostic information at the center of care. Cue Health
enables people to manage their health through real-time,
actionable, and connected health information, offering individuals
and their healthcare providers easy access to lab-quality
diagnostics anywhere, anytime, in a device that fits in the palm of
the hand. Cue Health's first-of-its-kind COVID-19 test was the
first FDA-authorized molecular diagnostic test for at-home and
over-the-counter use without a prescription and physician
supervision. Outside the United
States, Cue Health has received the CE mark in the European
Union, Interim Order authorization from Health Canada, regulatory
approval from India's Central
Drugs Standard Control Organization, and PSAR authorization from
Singapore's Health Sciences
Authority. Cue was founded in 2010 and is headquartered in
San Diego. For more information,
please visit www.cuehealth.com.
About Albertsons Companies
Albertsons Companies is a leading food and drug retailer in
the United States. As of
December 4, 2021, the Company
operated 2,278 retail food and drug stores with 1,722 pharmacies,
399 associated fuel centers, 22 dedicated distribution centers and
20 manufacturing facilities. The Company operates stores across 34
states and the District of
Columbia under more than 20 well-known banners including
Albertsons, Safeway, Vons, Jewel-Osco, Shaw's, Acme, Tom Thumb,
Randalls, United Supermarkets, Pavilions, Star Market, Haggen, Carrs, Kings Food Markets
and Balducci's Food Lovers Market. The Company is committed to
helping people across the country live better lives by making a
meaningful difference, neighborhood by neighborhood. In 2020, along
with the Albertsons Companies Foundation, the Company gave
$260 million in food and financial
support, including approximately $95
million through our Nourishing Neighbors Program to ensure
those living in our communities have enough to eat. Albertsons
Companies also pledged $5 million to
organizations supporting social justice. These efforts have helped
millions of people in the areas of hunger relief, education, cancer
research and treatment, social justice and programs for people with
disabilities and veterans' outreach.
Forward-Looking Statements
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
"forward-looking statements". The words, without limitation,
"anticipate," "believe," "continue," "could," "estimate," "expect,"
"intend," "may," "plan," "potential," "predict," "project,"
"should," "target," "will," "would" and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these or similar identifying
words. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including those related to the expected future diagnostic
test menu and the factors discussed in the "Risk Factors" section
of the Form 10-Q dated November 10,
2021 filed by Cue with the SEC. Any forward-looking
statements contained in this press release are based on the current
expectations of Cue's management team and speak only as of the date
hereof, and Cue specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
These products have not been FDA cleared or approved; but
have been authorized by FDA under an Emergency Use Authorization
(EUA). These products have been authorized only for the detection
of nucleic acid from SARS-CoV-2, not for any other viruses or
pathogens. The emergency use of these products is only authorized
for the duration of the declaration that circumstances exist
justifying the authorization of emergency use of in vitro
diagnostics for detection and/or diagnosis of COVID-19 under
Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21
U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or
authorization is revoked sooner.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cue-health-and-albertsons-companies-partner-to-provide-customers-with-fast-and-highly-accurate-covid-19-testing-in-pharmacies-across-the-us-301507701.html
SOURCE Cue Health Inc.